Fig. 2

p113 is upregulated and facilitates fatty acid oxidation and mitochondrial activity in NB. a Western blot assay showing the p113 levels in normal dorsal ganglia (DG), tumor (T) tissues of NB, and cultured tumor cell lines. b Western blot assay indicating the expression of p113 and CUX1 isoforms (p200 and p110) in SH-SY5Y, SH-N-SH, BE(2)-C, and IMR32 cells stably transfected with empty vector (mock), ecircCUX1, ecircCUX1 with ORF mutation (ecircCUX1 Mut), scramble shRNA (sh-Scb), or sh-ecircCUX1. c Western blot assay showing the cytoplasmic and nuclear accumulation of p113 in SH-SY5Y cells stably transfected with mock or p113. d Immunofluorescence assay revealing cytoplasmic and nuclear localization of p113 in SH-SY5Y and SK-N-SH cells stably transfected with Flag-tagged p113 (upper panel), and those in BE(2)-C and IMR32 cells (lower panel), with nuclei stained by DAPI (blue). Scale bar: 10 μm. e and f Heatmap (e) and quantification (f) of metabolite profiling assay indicating the fatty acid levels in SH-SY5Y and BE(2)-C cells stably transfected with mock, ecircCUX1, ecircCUX1 Mut, p113, sh-Scb, or sh-ecircCUX1 (n = 3). g Seahorse extracellular flux assay showing the oxygen consumption rate (OCR) levels in SH-SY5Y and BE(2)-C cells stably transfected with mock, ecircCUX1, ecircCUX1 Mut, p113, sh-Scb, or sh-ecircCUX1, and those treated with BSA or oleic acid (OLE, 200 μmol·L^− 1, n = 4). h Relative NAD⁺/NADH ratio and ATP levels in SH-SY5Y and BE(2)-C cells stably transfected with mock, ecircCUX1, ecircCUX1 Mut, p113, sh-Scb, or sh-ecircCUX1, and those treated with BSA or OLE (200 μmol·L^− 1, n = 5). ANOVA compared the difference in f-h. *P < 0.05 vs. mock, sh-Scb, or sh-Scb + BSA. Data are shown as mean ± s.e.m. (error bars) and representative of three independent experiments in a-d, g and h